Medartis Holding AG (SWX:MED)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.12B +7.0% |
| Revenue (ttm) | 307.05M +29.9% |
| Net Income | 14.92M |
| EPS | 1.20 |
| Shares Out | 12.45M |
| PE Ratio | 75.14 |
| Forward PE | 51.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,860 |
| Open | 90.00 |
| Previous Close | 90.40 |
| Day's Range | 86.90 - 91.00 |
| 52-Week Range | 70.60 - 97.50 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 101.67 (+12.84%) |
| Earnings Date | Aug 18, 2026 |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company’s medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for upper and lower extremities, mandible, midface, orthognathic under the APTUS and MODUS names, as well as CMX services through web portal,... [Read more]
Financial Performance
In 2025, Medartis Holding AG's revenue was 269.26 million, an increase of 19.76% compared to the previous year's 224.83 million. Earnings were 8.35 million, an increase of 136.65%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MED stock is "Buy." The 12-month stock price target is CHF 101.67, which is an increase of 12.84% from the latest price.
News
Medartis Holding AG Earnings Call Transcript: H1 2026
Revenue grew 31% year-over-year to CHF 160.8 million, with 17% organic growth and EBITDA margin rising to 18%. Upgraded guidance now targets 17%-19% organic sales growth for the year, driven by strong U.S. and EMEA performance and the successful KeriMedical TOUCH rollout.
Medartis Holding AG Quarterly report: H1 2026
Medartis Holding AG has published its H1 2026 quarterly earnings report on August 18, 2026.
Medartis Holding AG Slides: H1 2026
Medartis Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 18, 2026.
Medartis Holding AG Earnings release: H1 2026
Medartis Holding AG released its H1 2026 earnings on August 18, 2026, summarizing the period's financial results.
Medartis Holding AG Transcript: Investor update
Strong growth and innovation continue, with the TOUCH prosthesis driving rapid adoption and market expansion, especially in the U.S. and Europe. Financial guidance is reaffirmed, ESG and culture initiatives are advancing, and new production and education investments support scalability and long-term leadership.
Medartis Holding AG Slides: Investor update
Medartis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Medartis Holding AG Earnings Call Transcript: H2 2025
2025 saw double-digit organic growth, major acquisitions, and the successful U.S. launch of TOUCH, driving strong performance across all regions. Despite FX and tariff headwinds, margins improved and investments in production and innovation set the stage for 2026 growth.
Medartis Holding AG Annual report: H2 2025
Medartis Holding AG has published its H2 2025 annual report on March 17, 2026.
Medartis Holding AG Earnings release: H2 2025
Medartis Holding AG released its H2 2025 earnings on March 17, 2026, summarizing the period's financial results.
Medartis Holding AG Slides: H2 2025
Medartis Holding AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 17, 2026.